# OnCo record lu177-psma-it (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lu177-psma-it/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lu177-psma-it" ;
  schema:name "177Lu-PSMA-I&T"@en ;
  schema:description "177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit."@en ;
  schema:url <https://onco.cc/drugs/lu177-psma-it/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-presents-results-primary-analysis-phase-3-pivotal>, <https://www.onclive.com/view/177lu-psma-i-t-meets-rpfs-end-point-in-psma-mcrpc> ;
  onco:status "phase-3" ;
  onco:modality "Radioligand therapy (beta)" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/psma-pet/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:companies <https://onco.cc/companies/lantheus/>, <https://onco.cc/companies/curium/> ;
  onco:trials <https://onco.cc/trials/splash/>, <https://onco.cc/trials/eclipse-psma/> .